http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 04 Jun 2026 08:06:52 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Mirum+and+Incyte+to+present+zilurgisertib+study+results+at+ENDO+2026/26602814.html <p>Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) and Incyte Corp. (NASDAQ: INCY) announced that results from a Phase 2 study of zilurgisertib for fibrodysplasia ossificans progressiva will be presented at the Endocrine Society's annual meeting in June 2026.</p><p>The presentation will include data from Cohort 1 of the placebo-controlled PROGRESS study, which evaluated zilurgisertib in patients 12 years and older with the rare genetic disorder. These results formed the basis for the New Drug Application submitted to the U.S. Food and Drug Administration.</p><p>Zilurgisertib is an investigational oral ALK2 inhibitor designed to treat fibrodysplasia ossificans progressiva, a condition where soft tissues gradually turn into http://www.streetinsider.com/Corporate+News/Mirum+and+Incyte+to+present+zilurgisertib+study+results+at+ENDO+2026/26602814.html Thu, 04 Jun 2026 08:06:52 -0400 INCY MIRM http://www.streetinsider.com/Corporate+News/Mirum+and+Incyte+to+present+zilurgisertib+study+results+at+ENDO+2026/26602814.html <p>Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) and Incyte Corp. (NASDAQ: INCY) announced that results from a Phase 2 study of zilurgisertib for fibrodysplasia ossificans progressiva will be presented at the Endocrine Society's annual meeting in June 2026.</p><p>The presentation will include data from Cohort 1 of the placebo-controlled PROGRESS study, which evaluated zilurgisertib in patients 12 years and older with the rare genetic disorder. These results formed the basis for the New Drug Application submitted to the U.S. Food and Drug Administration.</p><p>Zilurgisertib is an investigational oral ALK2 inhibitor designed to treat fibrodysplasia ossificans progressiva, a condition where soft tissues gradually turn into http://www.streetinsider.com/Corporate+News/Mirum+and+Incyte+to+present+zilurgisertib+study+results+at+ENDO+2026/26602814.html Thu, 04 Jun 2026 08:06:52 -0400 INCY MIRM http://www.streetinsider.com/FDA/Mirum+and+Incyte+to+present+zilurgisertib+study+results+at+ENDO+2026/26602814.html <p>Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) and Incyte Corp. (NASDAQ: INCY) announced that results from a Phase 2 study of zilurgisertib for fibrodysplasia ossificans progressiva will be presented at the Endocrine Society's annual meeting in June 2026.</p><p>The presentation will include data from Cohort 1 of the placebo-controlled PROGRESS study, which evaluated zilurgisertib in patients 12 years and older with the rare genetic disorder. These results formed the basis for the New Drug Application submitted to the U.S. Food and Drug Administration.</p><p>Zilurgisertib is an investigational oral ALK2 inhibitor designed to treat fibrodysplasia ossificans progressiva, a condition where soft tissues gradually turn into http://www.streetinsider.com/FDA/Mirum+and+Incyte+to+present+zilurgisertib+study+results+at+ENDO+2026/26602814.html Thu, 04 Jun 2026 08:06:52 -0400 INCY MIRM http://www.streetinsider.com/FDA/Mirum+and+Incyte+to+present+zilurgisertib+study+results+at+ENDO+2026/26602814.html <p>Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) and Incyte Corp. (NASDAQ: INCY) announced that results from a Phase 2 study of zilurgisertib for fibrodysplasia ossificans progressiva will be presented at the Endocrine Society's annual meeting in June 2026.</p><p>The presentation will include data from Cohort 1 of the placebo-controlled PROGRESS study, which evaluated zilurgisertib in patients 12 years and older with the rare genetic disorder. These results formed the basis for the New Drug Application submitted to the U.S. Food and Drug Administration.</p><p>Zilurgisertib is an investigational oral ALK2 inhibitor designed to treat fibrodysplasia ossificans progressiva, a condition where soft tissues gradually turn into http://www.streetinsider.com/FDA/Mirum+and+Incyte+to+present+zilurgisertib+study+results+at+ENDO+2026/26602814.html Thu, 04 Jun 2026 08:06:52 -0400 INCY MIRM http://www.streetinsider.com/Press+Releases/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html <p class="bwalignc"> - <i>Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)</i> </p> <p> FOSTER CITY, Calif. &amp; WILMINGTON, Del.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (“FOP”) will be presented at ENDO 2026, the Endocrine Society’s annual meeting, taking place June 13-16, 2026, in Chicago, Illinois. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260604863826/en/" rel="nofollow">https://www.businesswire.com/news/home/20260604863826/en/</a></p><p> The late-breaking rapid-fire http://www.streetinsider.com/Press+Releases/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html Thu, 04 Jun 2026 08:05:00 -0400 A.06822034 INCY MIRM O.00160346 O.20026344 O.39152137 http://www.streetinsider.com/Press+Releases/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html <p class="bwalignc"> - <i>Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)</i> </p> <p> FOSTER CITY, Calif. &amp; WILMINGTON, Del.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (“FOP”) will be presented at ENDO 2026, the Endocrine Society’s annual meeting, taking place June 13-16, 2026, in Chicago, Illinois. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260604863826/en/" rel="nofollow">https://www.businesswire.com/news/home/20260604863826/en/</a></p><p> The late-breaking rapid-fire http://www.streetinsider.com/Press+Releases/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html Thu, 04 Jun 2026 08:05:00 -0400 A.06822034 INCY MIRM O.00160346 O.20026344 O.39152137 http://www.streetinsider.com/Press+Releases/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html <p class="bwalignc"> - <i>Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)</i> </p> <p> FOSTER CITY, Calif. &amp; WILMINGTON, Del.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (“FOP”) will be presented at ENDO 2026, the Endocrine Society’s annual meeting, taking place June 13-16, 2026, in Chicago, Illinois. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260604863826/en/" rel="nofollow">https://www.businesswire.com/news/home/20260604863826/en/</a></p><p> The late-breaking rapid-fire http://www.streetinsider.com/Press+Releases/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html Thu, 04 Jun 2026 08:05:00 -0400 A.06822034 INCY MIRM O.00160346 O.20026344 O.39152137 http://www.streetinsider.com/Press+Releases/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html <p class="bwalignc"> - <i>Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)</i> </p> <p> FOSTER CITY, Calif. &amp; WILMINGTON, Del.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (“FOP”) will be presented at ENDO 2026, the Endocrine Society’s annual meeting, taking place June 13-16, 2026, in Chicago, Illinois. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260604863826/en/" rel="nofollow">https://www.businesswire.com/news/home/20260604863826/en/</a></p><p> The late-breaking rapid-fire http://www.streetinsider.com/Press+Releases/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html Thu, 04 Jun 2026 08:05:00 -0400 A.06822034 INCY MIRM O.00160346 O.20026344 O.39152137 http://www.streetinsider.com/Press+Releases/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html <p class="bwalignc"> - <i>Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)</i> </p> <p> FOSTER CITY, Calif. &amp; WILMINGTON, Del.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (“FOP”) will be presented at ENDO 2026, the Endocrine Society’s annual meeting, taking place June 13-16, 2026, in Chicago, Illinois. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260604863826/en/" rel="nofollow">https://www.businesswire.com/news/home/20260604863826/en/</a></p><p> The late-breaking rapid-fire http://www.streetinsider.com/Press+Releases/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html Thu, 04 Jun 2026 08:05:00 -0400 A.06822034 INCY MIRM O.00160346 O.20026344 O.39152137 http://www.streetinsider.com/Press+Releases/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html <p class="bwalignc"> - <i>Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)</i> </p> <p> FOSTER CITY, Calif. &amp; WILMINGTON, Del.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (“FOP”) will be presented at ENDO 2026, the Endocrine Society’s annual meeting, taking place June 13-16, 2026, in Chicago, Illinois. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260604863826/en/" rel="nofollow">https://www.businesswire.com/news/home/20260604863826/en/</a></p><p> The late-breaking rapid-fire http://www.streetinsider.com/Press+Releases/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html Thu, 04 Jun 2026 08:05:00 -0400 A.06822034 INCY MIRM O.00160346 O.20026344 O.39152137 http://www.streetinsider.com/Business+Wire/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html <p class="bwalignc"> - <i>Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)</i> </p> <p> FOSTER CITY, Calif. &amp; WILMINGTON, Del.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (“FOP”) will be presented at ENDO 2026, the Endocrine Society’s annual meeting, taking place June 13-16, 2026, in Chicago, Illinois. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260604863826/en/" rel="nofollow">https://www.businesswire.com/news/home/20260604863826/en/</a></p><p> The late-breaking rapid-fire http://www.streetinsider.com/Business+Wire/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html Thu, 04 Jun 2026 08:05:00 -0400 A.06822034 INCY MIRM O.00160346 O.20026344 O.39152137 http://www.streetinsider.com/Business+Wire/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html <p class="bwalignc"> - <i>Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)</i> </p> <p> FOSTER CITY, Calif. &amp; WILMINGTON, Del.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (“FOP”) will be presented at ENDO 2026, the Endocrine Society’s annual meeting, taking place June 13-16, 2026, in Chicago, Illinois. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260604863826/en/" rel="nofollow">https://www.businesswire.com/news/home/20260604863826/en/</a></p><p> The late-breaking rapid-fire http://www.streetinsider.com/Business+Wire/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html Thu, 04 Jun 2026 08:05:00 -0400 A.06822034 INCY MIRM O.00160346 O.20026344 O.39152137 http://www.streetinsider.com/Business+Wire/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html <p class="bwalignc"> - <i>Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)</i> </p> <p> FOSTER CITY, Calif. &amp; WILMINGTON, Del.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (“FOP”) will be presented at ENDO 2026, the Endocrine Society’s annual meeting, taking place June 13-16, 2026, in Chicago, Illinois. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260604863826/en/" rel="nofollow">https://www.businesswire.com/news/home/20260604863826/en/</a></p><p> The late-breaking rapid-fire http://www.streetinsider.com/Business+Wire/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html Thu, 04 Jun 2026 08:05:00 -0400 A.06822034 INCY MIRM O.00160346 O.20026344 O.39152137 http://www.streetinsider.com/Business+Wire/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html <p class="bwalignc"> - <i>Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)</i> </p> <p> FOSTER CITY, Calif. &amp; WILMINGTON, Del.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (“FOP”) will be presented at ENDO 2026, the Endocrine Society’s annual meeting, taking place June 13-16, 2026, in Chicago, Illinois. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260604863826/en/" rel="nofollow">https://www.businesswire.com/news/home/20260604863826/en/</a></p><p> The late-breaking rapid-fire http://www.streetinsider.com/Business+Wire/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html Thu, 04 Jun 2026 08:05:00 -0400 A.06822034 INCY MIRM O.00160346 O.20026344 O.39152137 http://www.streetinsider.com/Business+Wire/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html <p class="bwalignc"> - <i>Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)</i> </p> <p> FOSTER CITY, Calif. &amp; WILMINGTON, Del.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (“FOP”) will be presented at ENDO 2026, the Endocrine Society’s annual meeting, taking place June 13-16, 2026, in Chicago, Illinois. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260604863826/en/" rel="nofollow">https://www.businesswire.com/news/home/20260604863826/en/</a></p><p> The late-breaking rapid-fire http://www.streetinsider.com/Business+Wire/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html Thu, 04 Jun 2026 08:05:00 -0400 A.06822034 INCY MIRM O.00160346 O.20026344 O.39152137 http://www.streetinsider.com/Business+Wire/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html <p class="bwalignc"> - <i>Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)</i> </p> <p> FOSTER CITY, Calif. &amp; WILMINGTON, Del.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (“FOP”) will be presented at ENDO 2026, the Endocrine Society’s annual meeting, taking place June 13-16, 2026, in Chicago, Illinois. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260604863826/en/" rel="nofollow">https://www.businesswire.com/news/home/20260604863826/en/</a></p><p> The late-breaking rapid-fire http://www.streetinsider.com/Business+Wire/Mirum+Pharmaceuticals+and+Incyte+Announce+Pivotal+Late-Breaking+Results+for+Zilurgisertib+in+Fibrodysplasia+Ossificans+Progressiva+Accepted+for+Presentation+at+ENDO+2026/26602801.html Thu, 04 Jun 2026 08:05:00 -0400 A.06822034 INCY MIRM O.00160346 O.20026344 O.39152137 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+May+29++Filed+by%3A+Ramasastry+Saira/26593922.html si-local-file:///var/storage/secattach/20260602/26593922.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+May+29++Filed+by%3A+Ramasastry+Saira/26593922.html Tue, 02 Jun 2026 19:50:00 -0400 MIRM O.39152137 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+May+29++Filed+by%3A+Ramasastry+Saira/26593922.html si-local-file:///var/storage/secattach/20260602/26593922.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+May+29++Filed+by%3A+Ramasastry+Saira/26593922.html Tue, 02 Jun 2026 19:50:00 -0400 MIRM O.39152137 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+May+29++Filed+by%3A+Fischer+Laurent/26593923.html si-local-file:///var/storage/secattach/20260602/26593923.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+May+29++Filed+by%3A+Fischer+Laurent/26593923.html Tue, 02 Jun 2026 19:50:00 -0400 MIRM O.39152137 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+May+29++Filed+by%3A+Fischer+Laurent/26593923.html si-local-file:///var/storage/secattach/20260602/26593923.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+May+29++Filed+by%3A+Fischer+Laurent/26593923.html Tue, 02 Jun 2026 19:50:00 -0400 MIRM O.39152137 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+May+29++Filed+by%3A+Walbert+Timothy+P/26593924.html si-local-file:///var/storage/secattach/20260602/26593924.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+May+29++Filed+by%3A+Walbert+Timothy+P/26593924.html Tue, 02 Jun 2026 19:50:00 -0400 MIRM O.39152137 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+May+29++Filed+by%3A+Walbert+Timothy+P/26593924.html si-local-file:///var/storage/secattach/20260602/26593924.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+May+29++Filed+by%3A+Walbert+Timothy+P/26593924.html Tue, 02 Jun 2026 19:50:00 -0400 MIRM O.39152137 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+Jun+01++Filed+by%3A+Peetz+Christopher/26593925.html si-local-file:///var/storage/secattach/20260602/26593925.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+Jun+01++Filed+by%3A+Peetz+Christopher/26593925.html Tue, 02 Jun 2026 19:50:00 -0400 MIRM O.39152137 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+Jun+01++Filed+by%3A+Peetz+Christopher/26593925.html si-local-file:///var/storage/secattach/20260602/26593925.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+Jun+01++Filed+by%3A+Peetz+Christopher/26593925.html Tue, 02 Jun 2026 19:50:00 -0400 MIRM O.39152137 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+May+29++Filed+by%3A+Cardon+Lon/26593926.html si-local-file:///var/storage/secattach/20260602/26593926.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Mirum+Pharmaceuticals%2C++++For%3A+May+29++Filed+by%3A+Cardon+Lon/26593926.html Tue, 02 Jun 2026 19:50:00 -0400 MIRM O.39152137